Explore more about: COVID-19

Share:

EmailFacebookLinkedInXWhatsAppShare
News
RADx Tech program has issued contracts to help meet the ongoing needs and challenges of COVID-19 diagnostic testing.
News
The National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx®) Tech program is working to identify necessary elements of at-home COVID-19 diagnostic test kits that may be used independently by people with disabilities.
News
Siemens Healthineers AG will supply 50 million rapid Covid-19 test kits as part of President Joe Biden‘s push to deliver 1 billion free at-home tests to Americans, the Defense Department said.
News
Fluidigm, "the South San Francisco-based company, which landed NIH money in a Shark Tank-style program for Covid-19 testing, announced that it will take on an investment worth $250 million from Casdin Capital and Viking Global investors, ". The company "will also rebrand, and call itself Standard BioTools.
News
Mammoth Biosciences has secured an emergency authorization from the FDA for its high-throughput COVID-19 test, which is powered by CRISPR gene-editing enzymes.
News
NIH RADx Tech Independent Test Assessment Program provides support for FDA authorization of two rapid at-home COVID-19 tests.
News
The NIH RADx initiative today announced the launch of the When To Test Calculator for Individuals, a companion to the version for organizations introduced last winter. By responding to just a few prompts, the new individual impact calculator indicates whether a person should get a test—now or soon.
News
NIH is investing $70 million from the American Rescue Plan to help bring more high-quality, at-home tests onto the market in the U.S. in coordination with the FDA. NIH’s new Independent Test Assessment Program (ITAP) will establish an accelerated pathway to support FDA evaluation of tests with potential for large-scale manufacturing.
News
The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.
News
A new $13.3 million contract from the NIH's Rapid Acceleration of Diagnostics (RADx) initiative will enable the David Geffen School of Medicine at UCLA to expand its capacity to process COVID-19 tests.